Hypoglossal Nucleus (Cn Xii) Motor Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The Hypoglossal Nucleus is the motor nucleus of the hypoglossal nerve (cranial nerve XII), located in the medulla oblongata. It controls the intrinsic and extrinsic muscles of the tongue, essential for speech, swallowing, and airway protection. This nucleus is prominently vulnerable in bulbar-onset ALS and other motor neuron diseases.
¶ Morphology and Markers
The hypoglossal nucleus contains:
- Lower Motor Neurons: Large, multipolar motor neurons with extensive dendritic arborizations
- Types: Bicer cells (slow-twitch), Fast-twitch units
- Somatotopic Organization: Neurons innervating different tongue muscle groups are spatially organized
Marker Genes:
- CHAT (choline acetyltransferase) - cholinergic motor neurons
- ISL1 (Islet LIM Homeobox 1) - motor neuron marker
- HB9 (MNX1) - motor neuron specification
- PHOX2B - cranial motor neuron marker
- Neurofilament proteins (NEFH, NEFM, NEFL)
- VAChT (Vesicular Acetylcholine Transporter)
Brain Regions: Medulla oblongata, dorsal surface, just lateral to the pyramid and medial to the dorsal motor nucleus of the vagus.
The hypoglossal nucleus controls all tongue movements:
- Speech Articulation: Innervates genioglossus, styloglossus, and hypoglossus muscles for vowel articulation and consonant production.
- Swallowing: Coordinates the oral phase of swallowing, moving food from the oral cavity to the pharynx.
- Airway Protection: Maintains airway patency, prevents aspiration during sleep.
- Mastication: Assists in food manipulation and chewing.
- Respiration: Upper airway dilator muscles maintain airway tone during breathing.
- Each hypoglossal motor neuron innervates approximately 10-25 muscle fibers (small motor units)
- Fast-fatigable, fast-fatigue-resistant, and slow motor unit types
- Bilateral cortical input via corticobulbar tract
The hypoglossal nucleus shows selective vulnerability in several neurological conditions:
- Pathology: Progressive loss of hypoglossal motor neurons, with TDP-43 inclusions.
- Mechanism: The hypoglossal nucleus is one of the first regions affected in bulbar-onset ALS.
- Clinical Correlation: Dysarthria (slurred speech), dysphagia (swallowing difficulty), tongue atrophy, fasciculations, and eventual respiratory failure.
- Pathology: Isolated degeneration of bulbar motor nuclei including hypoglossal.
- Mechanism: Part of the ALS-FTD spectrum with TDP-43 pathology.
- Clinical Correlation: Progressive speech and swallowing impairment.
- Pathology: X-linked recessive motor neuron disease affecting bulbar and spinal motor neurons.
- Mechanism: Androgen receptor polyglutamine expansion.
- Clinical Correlation: Progressive bulbar weakness, dysarthria, dysphagia.
- Pathology: α-Synuclein inclusions in the hypoglossal nucleus.
- Mechanism: Autonomic and motor system degeneration.
- Clinical Correlation: Dysphagia, dysarthria, and sleep-related breathing disorders.
- Pathology: Lewy bodies can be present in the hypoglossal nucleus.
- Mechanism: α-Synuclein affects motor nuclei.
- Clinical Correlation: Speech changes, swallowing difficulties in advanced PD.
- Pathology: Ischemic injury to the hypoglossal nucleus.
- Mechanism: Vascular occlusion (e.g., anterior spinal artery, vertebral artery).
- Clinical Correlation: Tongue weakness toward the side of the lesion, dysarthria.
Key differentially expressed genes in hypoglossal motor neurons include:
| Gene |
Expression |
Function |
| CHAT |
Very High |
Acetylcholine synthesis |
| SLC5A7 |
High |
Choline transporter |
| VAChT |
High |
Acetylcholine transport |
| ISL1 |
High |
Motor neuron transcription factor |
| MNX1 |
High |
HB9 - motor neuron specification |
| PHOX2B |
High |
Cranial motor neuron development |
| NEFL |
Very High |
Neurofilament light chain |
| NEFM |
High |
Neurofilament medium chain |
| SST |
Moderate |
Somatostatin - modulatory |
- Riluzole: Sodium channel blocker, modestly slows disease progression in ALS.
- Edaravone: Free radical scavenger, FDA-approved for ALS.
- AMX0035: Combination therapy targeting mitochondrial dysfunction and ER stress.
- Speech Augmentation: Speech-generating devices for communication.
- Feeding Tubes: Percutaneous endoscopic gastrostomy (PEG) for nutrition when dysphagia becomes severe.
- Non-invasive Ventilation: BiPAP for respiratory support.
- Tracheostomy: For airway protection in severe bulbar dysfunction.
- Hypoglossal Nerve Stimulation: Investigational for OSA and speech restoration.
- Stem Cell Therapy: Replacing lost motor neurons with stem cell-derived motor neurons.
- Gene Therapy: Targeting SOD1, C9orf72, and other ALS genes.
- Biomarkers: Using hypoglossal function as a biomarker for disease progression.
The study of Hypoglossal Nucleus (Cn Xii) Motor Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Sorensen JB, et al. (2019). Hypoglossal motor neuron vulnerability in ALS. Neurology. PMID:30610023.
- Kwon MJ, et al. (2017). Hypoglossal nucleus involvement in bulbar-onset ALS. Acta Neuropathologica. PMID:28255867.
- Van den Berg LH, et al. (2020). Molecular pathways in bulbar dysfunction in ALS. Brain. PMID:32191343.
- Pagano M, et al. (2018). Progressive bulbar palsy: Clinical features and pathology. Journal of Neurology. PMID:29354893.
- Wen J, et al. (2021). Sleep-disordered breathing in motor neuron disease. Sleep Medicine. PMID:33578089.
- Rousseau F, et al. (2016). Hypoglossal nerve stimulation for obstructive sleep apnea. Journal of Clinical Sleep Medicine. PMID:27019903.
- Kuffler DP, et al. (2019). Hypoglossal-facial anastomosis for facial nerve paralysis. Neurosurgical Review. PMID:30659681.
- Baker K, et al. (2018). Tongue dysfunction as an early marker in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. PMID:29369374.